| NCT Number | NCT06481592 |
| Lead Sponsor | Iovance Biotherapeutics, Inc. |
| Conditions | Endometrial Cancer |
| Enrollment | 60 participants |
| Start Date | 2024-10-29 |
| Primary Completion | 2028-05 (estimated) |
| Study Completion | 2029-11 (estimated) |
| Updated on ClinicalTrials.gov | 2025-10-30 |